CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients.
Authors:
- Daniela CriscuoloDCDaniela Criscuolo
- Francesco MerollaFMFrancesco Merolla
- Benedetta PellegrinoBPBenedetta Pellegrino
- Luca RussolilloLRLuca Russolillo
- Ilaria De BenedictisIBIlaria De Benedictis
- Daniela CalifanoDCDaniela Califano
- Rosaria CatalanoRCRosaria Catalano
- Carmela BavielloCBCarmela Baviello
- Silvia VarricchioSVSilvia Varricchio
- Sabrina C CecereSCSabrina C Cecere
- Camilla NeroCNCamilla Nero
- Eleonora PalluzziEPEleonora Palluzzi
Open Access
- 19 December 2026
- journal article
- biomarkers
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (1) , 201-210
Abstract
HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.Keywords
All Related Versions
Funding Information
- National Research Council, CNR, Rome (Progetto NUTRAGE)
- National Research Council, CNR, Rome (Progetto SerGenCovid)
- Regione Campania (POR FESR 2014–)
- Regione Campania (2020)
- Regione Campania (SATIN)
- Ministero dell'Università e della Ricerca (Prot. P2022TPPZL)
- Ministero dell'Università e della Ricerca (Project IR0000031)
- Fondazione AIRC per la ricerca sul cancro ETS (IG18921)
- Fondazione AIRC per la ricerca sul cancro ETS (IG25932)
- Agenzia Italiana del Farmaco, Ministero della Salute (RF-2016-02363995)
- Agenzia Italiana del Farmaco, Ministero della Salute (PNRR-MAD-2022-12375663)
- Ministero della Salute (L4/81_25)
This publication has 30 references indexed in Scilit:
- Homologous recombination and the repair of DNA double-strand breaksJournal of Biological Chemistry, 2018
- The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancerMolecular Cancer, 2018
- Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesOncotarget, 2017
- PARP inhibitors: Synthetic lethality in the clinicScience, 2017
- A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioningeLife, 2015
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerCancer Discovery, 2015
- Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA DamagePLOS ONE, 2012
- Involvement of H4(D10S170) protein in ATM-dependent response to DNA damageOncogene, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- H2AX: the histone guardian of the genomeDNA Repair, 2004